These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 18468546

  • 1. Non-peptide arginine-vasopressin antagonists: the vaptans.
    Decaux G, Soupart A, Vassart G.
    Lancet; 2008 May 10; 371(9624):1624-32. PubMed ID: 18468546
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y, Miura K, Iwao H.
    J Pharmacol Sci; 2014 May 10; 124(1):1-6. PubMed ID: 24401675
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic potential of vasopressin receptor antagonists.
    Ali F, Guglin M, Vaitkevicius P, Ghali JK.
    Drugs; 2007 May 10; 67(6):847-58. PubMed ID: 17428103
    [Abstract] [Full Text] [Related]

  • 4. [Vasopressin receptor antagonists: the vaptans].
    Villabona C.
    Endocrinol Nutr; 2010 May 10; 57 Suppl 2():41-52. PubMed ID: 21130961
    [Abstract] [Full Text] [Related]

  • 5. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 May 10; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 6. Vasopressin antagonists.
    Lemmens-Gruber R, Kamyar M.
    Cell Mol Life Sci; 2006 Aug 10; 63(15):1766-79. PubMed ID: 16794787
    [Abstract] [Full Text] [Related]

  • 7. [Use of "Vaptans" in treatment of hyponatremia].
    Tanındı A, Töre HF.
    Turk Kardiyol Dern Ars; 2015 Apr 10; 43(3):292-301. PubMed ID: 25906004
    [Abstract] [Full Text] [Related]

  • 8. The therapeutic use of vaptans for the treatment of dilutional hyponatremia.
    Cassagnol M, Shogbon AO, Saad M.
    J Pharm Pract; 2011 Aug 10; 24(4):391-9. PubMed ID: 21813818
    [Abstract] [Full Text] [Related]

  • 9. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.
    Prog Brain Res; 2002 Aug 10; 139():197-210. PubMed ID: 12436936
    [Abstract] [Full Text] [Related]

  • 10. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W, Głuszek J.
    Pol Arch Med Wewn; 2007 Aug 10; 117(8):356-62. PubMed ID: 18018383
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F, Raufi MA, Washington B, Ghali JK.
    Cardiovasc Drug Rev; 2007 Aug 10; 25(3):261-79. PubMed ID: 17919259
    [Abstract] [Full Text] [Related]

  • 13. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A.
    J Clin Endocrinol Metab; 2013 Apr 10; 98(4):1321-32. PubMed ID: 23401044
    [Abstract] [Full Text] [Related]

  • 14. [Vasopressin receptor antagonists and heart failure].
    Haass M.
    Ther Umsch; 2009 Nov 10; 66(11):735-40. PubMed ID: 19885790
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tolvaptan.
    Ghali JK, Hamad B, Yasothan U, Kirkpatrick P.
    Nat Rev Drug Discov; 2009 Aug 10; 8(8):611-2. PubMed ID: 19644472
    [Abstract] [Full Text] [Related]

  • 17. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G, Klapholz M.
    Cardiol Rev; 2009 Aug 10; 17(1):10-5. PubMed ID: 19092365
    [Abstract] [Full Text] [Related]

  • 18. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E, Gluud LL, Kimer N, Krag A.
    Aliment Pharmacol Ther; 2012 Oct 10; 36(7):619-26. PubMed ID: 22908905
    [Abstract] [Full Text] [Related]

  • 19. Vasopressin-receptor antagonists.
    Hoorn EJ, Zietse R.
    Future Cardiol; 2010 Jul 10; 6(4):523-34. PubMed ID: 20608824
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.